GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Shine-On BioMedical Co 6926.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

58.90

+6.13%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Shine-On BioMedical Co

Its shares trade on Taipei Exchange under the ticker 6926.TWO. It has been listed since 25 November 2022. In the fiscal year to 31 December 2025, it reported revenue of TWD 30.0m and a net loss of TWD 110.3m. At that date it held total assets of TWD 950.9m and shareholders' equity of TWD 907.3m.

Shine-On BioMedical Co., Ltd. engages in the research, development, manufacture, and sale of anti-cancer products. The company is headquartered in Taichung, Taichung. The company went IPO on 2022-11-25. Antibody products include trispecific T cell engaging nanobody (SOA101), EphA10 trispecific antibody engaging immune cells (SOA201), iNb Intrabody nanoscale intracellular specific antibody drug (SOA102), iNb STAR TriTE T cell receptor Nano-scale trispecific antibody drug (SOA103). Nucleic acid drugs include exosome-carrying nucleic acid and chemotherapy drugs (SOB101).

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
25 Nov 2022
Employees
16

Leadership

Pay as last reported

  • Qiujin HuangChairman of the Board, since 2025
  • Yunru ChenFinance Director, Corporate Governance Officer
  • Huijun HeDeputy General Manager-R&D
  • Fugui WuDirector
  • Mr. Jung-Cheng HsiehIndependent Director
  • Rongsheng XieIndependent Director
  • Jiazhu ZhangIndependent Director
  • Zhihan ZhangIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Shine-On BioMedical's SOA101 trispecific T cell engaging nanobody targets cancer cells effectively.
  • The company's SOA201 EphA10 trispecific antibody engages immune cells for cancer treatment.
  • Shine-On BioMedical's SOA102 iNb Intrabody nanoscale drug targets intracellular cancer markers.

Weaknesses

  • Shine-On BioMedical has only 16 full-time employees, limiting operational capacity.
  • The company's IPO on 25 November 2022 indicates limited market experience.
  • Shine-On BioMedical's product portfolio is concentrated in anti-cancer drugs only.

Opportunities

  • Shine-On BioMedical can expand its SOB101 exosome-carrying nucleic acid drug in the Asian market.
  • The company can leverage its Taichung headquarters for regional biotechnology collaborations.
  • Shine-On BioMedical may grow through partnerships in the Health Care sector.

Threats

  • Shine-On BioMedical faces competition from established biotechnology firms in Taiwan.
  • The company's small size may hinder its ability to secure large-scale funding.
  • Regulatory challenges in the Health Care industry could delay product approvals.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.